Cogent Biosciences (Nasdaq: COGT) will participate in the Jefferies Global Healthcare Conference in New York on June 3, 2026 at 11:05 a.m. ET. A live webcast and 30‑day replay will be available on the company’s investor website.
The company also granted inducement equity awards under its 2020 Inducement Plan to six new employees on May 26, 2026. Awards total 25,500 stock options and 18,700 RSUs, with 4‑year vesting schedules, in line with Nasdaq Listing Rule 5635(c)(4).
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – COGT
+1.68%
3 alerts
+1.68%Session close to close
$5.90BMarket Cap
6.25KVolume
In the May 27 session, COGT gained 1.68%, reflecting a mild positive market reaction.
Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility.
This announcement highlights Cogent’s participation at the Jefferies conference on June 3, 2026 and ...
Analysis
This announcement highlights Cogent’s participation at the Jefferies conference on June 3, 2026 and inducement equity awards totaling 25,500 options and 18,700 RSUs for 6 new employees. Against a backdrop of recent NDAs and positive Phase 3 data, the news signals continued outreach and team expansion. Investors may watch future updates around late‑stage bezuclastinib programs and capital allocation decisions alongside ongoing corporate governance and compensation disclosures.
Key Figures
Current price:$33.895Price vs 52-week high:-22.49%Inducement option grants:25,500 shares+5 more
8 metrics
Current price$33.895Prior close before this news
Price vs 52-week high-22.49%Relative to 52-week high $43.73
Inducement option grants25,500 sharesNonqualified stock options to new employees
Inducement RSUs18,700 unitsRestricted stock units granted to new employees
Employees receiving awards6 employeesNew hires under 2020 Inducement Plan
NDA for bezuclastinib in imatinib‑resistant GIST with strong Phase 3 data.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent news, especially positive clinical and data presentations, often led to modest moves, with occasional negative reactions even on strong clinical updates and NDA milestones.
Recent Company History
Over the last few months, Cogent reported several key milestones. On Apr 1 it submitted an NDA for bezuclastinib in GIST with Phase 3 data showing a 50% risk reduction, yet shares fell 8.44%. Positive preclinical oncology data at AACR on Apr 17 drove a 2.93% gain. Subsequent positive Phase 3 PEAK and EHA presentation news produced smaller, mixed reactions. Today’s conference and inducement grant announcement fits a pattern of ongoing investor communications alongside an advanced pipeline.
Key Terms
nonqualified options, restricted stock units (rsus), nasdaq listing rule 5635(c)(4), exercise price, +1 more
5 terms
nonqualified optionsfinancial
"The employees received, in the aggregate, (i) nonqualified options to purchase 25,500 shares"
Nonqualified options are employee stock options that give a holder the right to buy company shares at a set price for a limited period, like a coupon letting you buy a product later at today’s price. They matter to investors because when exercised the difference between market price and the set price is taxed as regular income (affecting the holder’s tax bill) and can dilute existing shares and create a tax deduction for the company.
restricted stock units (rsus)financial
"and (ii) 18,700 restricted stock units (RSUs). Each option has a 10-year term"
Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.
nasdaq listing rule 5635(c)(4)regulatory
"The awards were approved in accordance with Listing Rule 5635(c)(4) of the corporate"
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
exercise pricefinancial
"Each option has a 10-year term, an exercise price equal to the closing price"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting schedulefinancial
"and a 4-year vesting schedule with 25% vesting on the 1-year anniversary"
A vesting schedule is a timeline that determines when someone gains full ownership of certain benefits, such as company stock or retirement contributions. Think of it like earning the right to own a gift gradually over time, rather than receiving it all at once. It matters to investors because it affects when they can fully access or sell these benefits, influencing their financial planning and decision-making.
WALTHAM, Mass. and BOULDER, Colo., May 27, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced its participation in the Jefferies Global Healthcare Conference in New York on Wednesday, June 3, 2026 at 11:05 a.m. ET.
A live webcast will be available on the Investors & Media page of Cogent’s website at investors.cogentbio.com. A replay of the webcast will be available approximately two hours after the completion of the event and will be archived for up to 30 days.
Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Cogent also announced today that, on May 26, 2026, the Compensation Committee of Cogent’s Board of Directors, made up entirely of independent directors, approved the grants of “inducement” equity awards to six new employees under the company’s 2020 Inducement Plan with a grant date of May 26, 2026. The awards were approved in accordance with Listing Rule 5635(c)(4) of the corporate governance rules of the Nasdaq Stock Market. The employees received, in the aggregate, (i) nonqualified options to purchase 25,500 shares of Cogent common stock and (ii) 18,700 restricted stock units (RSUs). Each option has a 10-year term, an exercise price equal to the closing price of Cogent’s common stock on the grant date, and a 4-year vesting schedule with 25% vesting on the 1-year anniversary of the grant date and the remainder vesting in equal monthly installments over the subsequent 36 months, provided such employee remains employed through each such vesting date. The RSUs vest annually in equal installments over 4 years from the grant date, provided such employee remains employed through each such vesting date.
About Cogent Biosciences, Inc. Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving Systemic Mastocytosis, a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced Gastrointestinal Stromal Tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. In addition, the Cogent Research Team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases targeting mutations in ErbB2, PI3Kα, KRAS and JAK2. Cogent Biosciences is based in Waltham, MA and Boulder, CO. Visit our website for more information at www.cogentbio.com. Follow Cogent Biosciences on social media: X (formerly known as Twitter) and LinkedIn. Information that may be important to investors will be routinely posted on our website and X.
When will Cogent Biosciences (COGT) present at the 2026 Jefferies Global Healthcare Conference?
Cogent Biosciences will present at the Jefferies Global Healthcare Conference on June 3, 2026 at 11:05 a.m. ET. According to Cogent, the session will be held in New York with a live webcast for investors.
How can investors watch Cogent Biosciences’ June 3, 2026 Jefferies conference webcast?
Investors can watch Cogent Biosciences’ webcast via the Investors & Media page at investors.cogentbio.com. According to Cogent, a replay will be available about two hours after the event and archived for up to 30 days.
What inducement equity awards did Cogent Biosciences (COGT) grant on May 26, 2026?
On May 26, 2026, Cogent Biosciences granted inducement equity awards to six new employees under its 2020 Inducement Plan. According to Cogent, these total 25,500 stock options and 18,700 restricted stock units (RSUs).
What are the vesting terms for Cogent Biosciences’ 25,500 stock options granted in May 2026?
The 25,500 nonqualified options vest over four years, with 25% after one year and the rest monthly over 36 months. According to Cogent, each option has a 10‑year term and an exercise price equal to the grant‑date closing price.
How do Cogent Biosciences’ 18,700 RSUs granted in May 2026 vest for employees?
The 18,700 RSUs vest in equal annual installments over four years from the May 26, 2026 grant date. According to Cogent, vesting requires continued employment through each vesting date for the participating employees.
Are Cogent Biosciences’ May 26, 2026 inducement grants compliant with Nasdaq rules?
Cogent Biosciences states that the May 26, 2026 inducement equity awards were approved under Nasdaq Listing Rule 5635(c)(4). According to Cogent, the independent Compensation Committee granted them under the company’s 2020 Inducement Plan.
